How Size Exclusion Chromatography can improve processes and quality in biopharmaceutical development

Log in to watch this webinar

Not registered yet? Konto erstellen
00:00:00 How Size Exclusion Chromatography can improve processes and quality in biopharmaceutical development
00:01:17 Outline
00:02:20 Life sciences
00:02:59 Life science market sector
00:04:15 Development pipeline
00:05:23 Desired information
00:06:46 Life science sample considerations
00:08:09 Overview of SEC
00:09:09 What Is Chromatography?
00:10:18 Size Exclusion Chromatography
00:12:31 The Separation Process
00:15:24 SEC road map
00:17:03 The Detectors
00:18:52 SEC in life science applications
00:19:24 SEC in life science applications
00:21:44 Why OMNISEC is perfect for life science samples
00:22:42 Sample types suitable for SEC
00:25:07 Life science applications
00:26:51 Proteasome 20S loaded with Cytochrome C
00:28:49 Stretched Protein vs. Globular Protein
00:30:19 Intrinsic Viscosity for Proteins
00:31:22 Antibody Conformational Analysis
00:32:43 Conformational Changes
00:33:37 Conformational Changes
00:34:16 Compositional Analysis
00:35:23 Compositional Analysis
00:36:34 PEGylated Proteins – Compositional Analysis
00:37:14 PEGylated Proteins – Compositional Analysis
00:38:15 Protein Detergent Complex (PDC)
00:39:52 Conclusions
00:40:57 Thank you for your attentionAny questions?
00:45:13 Contact Information
Size Exclusion Chromatography (SEC) is a valuable technique for the analysis of macromolecules such as proteins, antibodies, and polysaccharides. Characterization of these materials is essential for many applications, ranging from pharmaceutical/biopharmaceutical manufacturing and development to drug delivery.

As such, SEC has become a fixture in research and QC labs to provide molecular weight, size, shape, purity, and additional information, allowing scientists to exert maximum control over their processes and improve product characteristics and quality.

This webinar will explore the molecular characterization information made available by SEC, and will include some relevant examples to touch upon how this data can assist throughout the drug development pipeline.